Sanofi India Past Earnings Performance
Past criteria checks 2/6
Sanofi India has been growing earnings at an average annual rate of 12.5%, while the Pharmaceuticals industry saw earnings growing at 14.2% annually. Revenues have been declining at an average rate of 1.1% per year. Sanofi India's return on equity is 59.4%, and it has net margins of 21.1%.
Key information
12.5%
Earnings growth rate
12.5%
EPS growth rate
Pharmaceuticals Industry Growth | 17.5% |
Revenue growth rate | -1.1% |
Return on equity | 59.4% |
Net Margin | 21.1% |
Next Earnings Update | 13 May 2024 |
Recent past performance updates
Recent updates
Revenue & Expenses BreakdownBeta
How Sanofi India makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
---|---|---|---|---|
31 Dec 23 | 28,511 | 6,029 | 3,706 | 0 |
30 Sep 23 | 28,291 | 5,961 | 4,178 | 0 |
30 Jun 23 | 28,064 | 5,751 | 4,219 | 0 |
31 Mar 23 | 27,996 | 5,726 | 4,323 | 0 |
31 Dec 22 | 27,701 | 6,206 | 4,414 | 0 |
30 Sep 22 | 27,861 | 5,801 | 4,603 | 0 |
30 Jun 22 | 28,487 | 9,790 | 4,704 | 0 |
31 Mar 22 | 29,385 | 10,369 | 4,783 | 0 |
31 Dec 21 | 29,566 | 9,444 | 4,836 | 0 |
30 Sep 21 | 29,890 | 9,770 | 4,885 | 0 |
30 Jun 21 | 29,211 | 5,801 | 4,907 | 0 |
31 Mar 21 | 28,425 | 5,381 | 5,024 | 0 |
31 Dec 20 | 29,019 | 4,776 | 5,164 | 0 |
30 Sep 20 | 30,079 | 4,519 | 5,635 | 0 |
30 Jun 20 | 31,004 | 4,456 | 5,709 | 0 |
31 Mar 20 | 31,378 | 4,067 | 4,664 | 0 |
31 Dec 19 | 30,706 | 4,142 | 5,446 | 0 |
30 Sep 19 | 29,707 | 3,962 | 5,269 | 0 |
30 Jun 19 | 29,354 | 3,888 | 5,145 | 0 |
31 Mar 19 | 28,704 | 3,910 | 5,008 | 0 |
31 Dec 18 | 27,708 | 3,806 | 4,928 | 0 |
30 Sep 18 | 26,870 | 3,773 | 4,773 | 0 |
30 Jun 18 | 26,107 | 3,744 | 4,694 | 0 |
31 Mar 18 | 25,284 | 3,485 | 4,639 | 0 |
31 Dec 17 | 24,636 | 3,260 | 4,576 | 0 |
30 Sep 17 | 23,747 | 2,953 | 4,426 | 0 |
30 Jun 17 | 23,454 | 2,619 | 4,393 | 0 |
31 Mar 17 | 23,650 | 2,744 | 4,288 | 0 |
31 Dec 16 | 23,668 | 3,042 | 4,221 | 0 |
30 Sep 16 | 23,452 | 2,989 | 4,242 | 0 |
30 Jun 16 | 23,068 | 2,909 | 4,118 | 0 |
31 Mar 16 | 22,486 | 2,699 | 3,382 | 0 |
31 Dec 15 | 21,931 | 2,377 | 4,000 | 0 |
30 Sep 15 | 21,363 | 2,111 | 6,231 | 0 |
30 Jun 15 | 20,654 | 2,005 | 6,136 | 0 |
31 Mar 15 | 20,215 | 1,938 | 6,052 | 0 |
31 Dec 14 | 19,775 | 1,971 | 3,555 | 0 |
30 Sep 14 | 19,539 | 2,384 | 5,582 | 0 |
30 Jun 14 | 19,364 | 2,534 | 5,471 | 0 |
31 Mar 14 | 18,657 | 2,471 | 5,389 | 0 |
31 Dec 13 | 18,089 | 2,398 | 5,320 | 0 |
30 Sep 13 | 17,252 | 2,174 | 4,970 | 0 |
30 Jun 13 | 16,493 | 1,916 | 4,853 | 0 |
Quality Earnings: 500674 has a high level of non-cash earnings.
Growing Profit Margin: 500674's current net profit margins (21.1%) are lower than last year (22.4%).
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: 500674's earnings have grown by 12.5% per year over the past 5 years.
Accelerating Growth: 500674's has had negative earnings growth over the past year, so it can't be compared to its 5-year average.
Earnings vs Industry: 500674 had negative earnings growth (-2.9%) over the past year, making it difficult to compare to the Pharmaceuticals industry average (23.1%).
Return on Equity
High ROE: 500674's Return on Equity (59.4%) is considered outstanding.